Immunogenicity and Safety of Measles Vaccine in HIV-infected Children: an Updated Systematic Review.
Human immunodeficiency virus (HIV)-infected children are at increased risk of measles morbidity and mortality. We searched abstracts from the PubMed, Embase, and Latin American and Caribbean Health Sciences databases for articles published from the earliest date available through September 26, 2017. The primary outcome of interest was serologic responses to measles vaccine stratified by HIV infection status. A total of 2,858 potentially eligible articles were identified, and the final review included 12 studies published between 1992 and 2013, nine of which reported data on vaccine safety. The included studies represented 3,573 children, at least 335 of whom were HIV-infected, 788 HIV-exposed but uninfected, and 1,478 HIV-unexposed. Four of the 12 studies found statistically significant reductions in seropositivity among HIV-infected children compared to HIV-uninfected children within 4 months of vaccination (prevalence ratio range: 0.44-0.70), and forest plots provided visual trends of decreasing immunity over time among HIV-infected children in two additional studies. No vaccine-related deaths or serious adverse events were reported. The updated review demonstrated limitations of the existing published literature but supported evidence of reduced immunogenicity of measles vaccine among HIV-infected children, supporting the World Health Organization recommendation to revaccinate HIV-infected children against measles following immune reconstitution with combination antiretroviral therapy.